Tag: GLP-1
As GLP-1 use rises, so does awareness of sleep apnea, says Blackstone CEO
February 6, 2026Theresa Flaherty, Managing Editor
TAMPA, Fla. – With Novo Nordisk’s pill version of Wegovy now widely available, GLP-1 drugs are poised for even greater adoption. That surge is fueling awareness of the link between obesity and sleep apnea – and driving demand for sleep testing, says Vick Tipnes, CEO and founder of Blackstone Medical Services.
Fortunately, people recognize there's a connection between health concerns like being overweight and the risk of having...
Resmed highlights AI-driven CPAP tech, competitive bidding win and GLP-1 insights at J.P. Morgan Healthcare Conference
January 16, 2026Liz Beaulieu, Editor
SAN FRANCISCO – Resmed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Smart Comfort, will help improve both short- and long-term compliance with therapy.
Resmed announced in late 2025 that the U.S. Food and Drug Administration (FDA) had cleared Smart Comfort. The technology will launch in a limited beta in early 2026 for new...
Do weight-loss drugs reduce need for CPAP? Modestly, according to new research
December 30, 2025HME News Staff
YARMOUTH, Maine – Popular weight-loss drugs, especially tirzepatide, are linked to modestly lower CPAP initiation among adults with Type 2 diabetes and obstructive sleep apnea (OSA), according to a research letter in the Journal of the American Medical Association (JAMA). Researchers found a stronger link between the drugs and reduced hospitalization and mortality. “These findings align with recent randomized clinical trials showing...
In brief: CMS lifts claims hold, Eli Lilly drafts Shaq, Menlo Ventures surveys AI adoption
October 29, 2025HME News Staff
WASHINGTON – CMS has instructed all Medicare Administrative Contractors (MACs) to lift the claims hold and process claims with dates of service Oct. 1, 2025, and later for certain services impacted by select expired Medicare legislative payment provisions passed under the Full-Year Continuing Appropriations and Extensions Act of 2025.
This includes claims paid under the:
Medicare Physician Fee Schedule
Ground ambulance transport
Federally Qualified Health...
Eli Lilly, O’Neal 'break through stigma’ of obstructive sleep apnea
October 28, 2025HME News Staff
INDIANAPOLIS – Eli Lilly has a new partnership with NBA Hall of Famer and cultural icon Shaquille O’Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA).
The campaign aims to educate the public about symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity, the company says.
"Moderate-to-severe...
Resmed advocates for fair reimbursement, stands behind CPAP
August 1, 2025Liz Beaulieu, Editor
SAN DIEGO – Resmed CEO Mick Farrell addressed the latest potential threats to the CPAP therapy market during a recent webcast: The resurgence of Medicare’s competitive bidding program and the development of a new pill to treat obstructive sleep apnea (OSA).
Questioning bid program, savings
Farrell said Resmed is discussing competitive bidding directly with leadership at Health and Human Services and CMS, and working with AAHomecare and AdvaMed to respond to the proposed...
GLP-1s fuel shift in sleep care
June 26, 2025Tracy Orzel
Once pushed aside by the pressures of work and productivity, sleep is now at the center of how patients, providers and society think about well-being.
“We now understand that poor sleep doesn’t just leave you feeling tired, it’s linked to serious, chronic conditions, such as high blood pressure and diabetes,” said Dr. Carlos Nunez, chief medical officer at Resmed.
This shift is driving an unprecedented surge in demand for sleep therapy, with a growing confluence...
New report shows diabetes spending levels off as GLP-1 use, cost controls rise
June 24, 2025HME News Staff
SALT LAKE CITY – After decades of increases, diabetes-related health care costs have plateaued, according to a new Trends in Spend report from Nomi Health.
To build the report, the company analyzed employer-sponsored claims data from 2021-24 and found that, while overall health care costs continue to climb, diabetes costs have leveled off.
“For years, diabetes has been one of the biggest and fastest-growing costs for employers,” said Mark Newman, CEO and co-founder...
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
January 31, 2025Liz Beaulieu, Editor
SAN DIEGO – In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep apnea, ResMed is ramping up its education to high-volume prescribers of GLP-1 drugs to reiterate that PAP therapy remains the gold standard.
The FDA announced in late December that it had approved Eli Lilly's Zepbound (tirzepatide) for the treatment of moderate to severe OSA in adults with obesity. It’s approved for use in combination...
In brief: Medline’s IPO, GLP-1's expansion, DME’s ‘hidden cost,’ Nymbl’s investment
January 3, 2025HME News Staff
NORTHFIELD, Ill. – Medline has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock.
The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.
In 2021, Medline announced it had received outside...